CLC number: R735; R457
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2015-04-10
Cited: 2
Clicked: 5316
Jin-ting Yang, Li-hui Tang, Yun-qing Liu, Yin Wang, Lie-ju Wang, Feng-jiang Zhang, Min Yan. Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes[J]. Journal of Zhejiang University Science B, 2015, 16(5): 395-403.
@article{title="Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes",
author="Jin-ting Yang, Li-hui Tang, Yun-qing Liu, Yin Wang, Lie-ju Wang, Feng-jiang Zhang, Min Yan",
journal="Journal of Zhejiang University Science B",
volume="16",
number="5",
pages="395-403",
year="2015",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1400224"
}
%0 Journal Article
%T Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes
%A Jin-ting Yang
%A Li-hui Tang
%A Yun-qing Liu
%A Yin Wang
%A Lie-ju Wang
%A Feng-jiang Zhang
%A Min Yan
%J Journal of Zhejiang University SCIENCE B
%V 16
%N 5
%P 395-403
%@ 1673-1581
%D 2015
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1400224
TY - JOUR
T1 - Cisplatin combined with hyperthermia kills HepG2 cells in intraoperative blood salvage but preserves the function of erythrocytes
A1 - Jin-ting Yang
A1 - Li-hui Tang
A1 - Yun-qing Liu
A1 - Yin Wang
A1 - Lie-ju Wang
A1 - Feng-jiang Zhang
A1 - Min Yan
J0 - Journal of Zhejiang University Science B
VL - 16
IS - 5
SP - 395
EP - 403
%@ 1673-1581
Y1 - 2015
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1400224
Abstract: The safe use of intraoperative blood salvage (IBS) in cancer surgery remains controversial. Here, we investigated the killing effect of cisplatin combined with hyperthermia on human hepatocarcinoma (HepG2) cells and erythrocytes from IBS in vitro. hepG2 cells were mixed with concentrated erythrocytes and pretreated with cisplatin (50, 100, and 200 μg/ml) alone at 37 °C for 60 min and cisplatin (25, 50, 100, and 200 μg/ml) combined with hyperthermia at 42 °C for 60 min. After pretreatment, the cell viability, colony formation and DNA metabolism in HepG2 and the Na+-K+-ATPase activity, 2,3-diphosphoglycerate (2,3-DPG) concentration, free hemoglobin (Hb) level, osmotic fragility, membrane phosphatidylserine externalization, and blood gas variables in erythrocytes were determined. Pretreatment with cisplatin (50, 100, and 200 μg/ml) combined with hyperthermia (42 °C) for 60 min significantly decreased HepG2 cell viability, and completely inhibited colony formation and DNA metabolism when the HepG2 cell concentration was 5×104 ml−1 in the erythrocyte (P<0.01). Erythrocytic Na+-K+-ATPase activity, 2,3-DPG level, phosphatidylserine externalization, and extra-erythrocytic free Hb were significantly altered by hyperthermia plus high concentrations of cisplatin (100 and 200 μg/ml) (P<0.05), but not by hyperthermia plus 50 μg/ml cisplatin (P>0.05). In conclusion, pretreatment with cisplatin (50 μg/ml) combined with hyperthermia (42 °C) for 60 min effectively eliminated hepG2 cells from IBS but did not significantly affect erythrocytes in vitro.
[1]Adias, T.C., Jeremiah, Z., Uko, E., et al., 2006. Autologous blood transfusion—a review. S. Afr. J. Surg., 44(3):114-116, 118.
[2]Catling, S., Williams, S., Freites, O., et al., 2008. Use of a leucocyte filter to remove tumour cells from intra-operative cell salvage blood. Anaesthesia, 63(12):1332-1338.
[3]Edelman, M.J., Potter, P., Mahaffey, K.G., et al., 1996. The potential for reintroduction of tumor cells during intraoperative blood salvage: reduction of risk with use of the RC-400 leukocyte depletion filter. Urology, 47(2):179-181.
[4]Fӧller, M., Braun, M., Qadri, S.M., et al., 2010. Temperature sensitivity of suicidal erythrocyte death. Eur. J. Clin. Invest., 40(6):534-540.
[5]Hansen, E., Wolff, N., Knuechel, R., et al., 1995. Tumor cells in blood shed from the surgical field. Arch. Surg., 130(4): 387-393.
[6]Hansen, E., Knuechel, R., Altmeppen, J., et al., 1999. Blood irradiation for intraoperative autotransfusion in cancer surgery: demonstration of efficient elimination of contaminating tumor cells. Transfusion, 39(6):608-615.
[7]Harrison, L.E., Bryan, M., Pliner, L., et al., 2008. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann. Surg. Oncol., 15(5):1407-1413.
[8]Hartmann, S., Kriegebaum, U., Küchler, N., et al., 2014. Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells. Clin. Oral Investig., 18(1):189-197.
[9]Hasegawa, A., Shimizu, R., Mohandas, N., et al., 2012. Mature erythrocyte membrane homeostasis is compromised by loss of the GATA1-FOG1 interaction. Blood, 119(11):2615-2623.
[10]Herron, D.M., Grabowy, R., Connolly, R., et al., 1997. The limits of bloodwarming: maximally heating blood with an inline microwave bloodwarmer. J. Trauma, 43(2):219-228.
[11]Hildebrandt, B., Wust, P., Ahlers, O., et al., 2002. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol., 43(1):33-56.
[12]Issels, R.D., 2008. Hyperthermia adds to chemotherapy. Eur. J. Cancer, 44(17):2546-2554.
[13]Jemal, A., Center, M.M., Desantis, C., et al., 2010. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev., 19(8):1893-1907.
[14]Kiefer, C.R., Snyder, L.M., 2000. Oxidation and erythrocyte senescence. Curr. Opin. Hematol., 7(2):113-116.
[15]Kumar, N., Chen, Y., Zaw, A.S., et al., 2014. Use of intraoperative cell-salvage for autologous blood transfusions in metastatic spine tumour surgery: a systematic review. Lancet Oncol., 15(1):e33-e41.
[16]Moretto, J., Chauffert, B., Ghiringhelli, F., et al., 2011. Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator. Invest. New Drugs, 29(6):1164-1176.
[17]Sachar, S., Saxena, R.K., 2011. Cytotoxic effect of poly-dispersed single walled carbon nanotubes on erythrocytes in vitro and in vivo. PLoS ONE, 6(7):e22032.
[18]Su, X.Y., Yin, H.T., Li, S.Y., et al., 2012. Intervention effects of nedaplatin and cisplatin on proliferation and apoptosis of human tumour cells in vitro. Asian Pac. J. Cancer Prev., 13(9):4531-4536.
[19]Sugarbaker, P.H., 2007. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int. J. Hyperthermia, 23(5):431-442.
[20]Wang, X., Ji, B., Zhang, Y., et al., 2012. Comparison of the effects of three cell saver devices on erythrocyte function during cardiopulmonary bypass procedure—a pilot study. Artif. Organs, 36(10):931-935.
[21]Waters, J.H., Donnenberg, A.D., 2009. Blood salvage and cancer surgery: should we do it? Transfusion, 49(10):2016-2018.
[22]Waters, J.H., Yazer, M., Chen, Y.F., et al., 2012. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion, 52(10):2167-2173.
[23]Westermann, A.M., Grosen, E.A., Katschinski, D.M., et al., 2001. A pilot study of whole body hyperthermia and carboplatin in platinum-resistant ovarian cancer. Eur. J. Cancer, 37(9):1111-1117.
[24]Winslow, R.M., 2007. The role of hemoglobin oxygen affinity in oxygen transport at high altitude. Respir. Physiol. Neurobiol., 158(2-3):121-127.
[25]Wu, J.B., Lei, W.F., Zhao, L.Y., et al., 2006. Hyperthermia: its effectiveness in killing tumor cells and influence on Na+-K+-ATPase activities in erythrocytes. Chin. J. Anesthesiol., 26(3):258-260 (in Chinese).
[26]Zhou, J.F., Wang, P., Lei, W.F., 2011. Effectiveness of cis-diamminedichloroplatinum combined with hyperthermia in killing liver tumor cells and its influence on erythrocytes in vitro. Chin. J. Anesthesiol., 31(2):193-196 (in Chinese).
Open peer comments: Debate/Discuss/Question/Opinion
<1>